Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02892799
Other study ID # 1050087
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 12, 2015
Est. completion date December 2020

Study information

Verified date April 2019
Source Intermountain Health Care, Inc.
Contact Michael Lanspa, MD
Phone 801-408-5060
Email michael.lanspa@imail.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For patients with a condition called acute respiratory distress syndrome (ARDS), managing their fluid levels to achieve a negative balance helps to improve their outcomes. In the past, patients' fluid levels were monitored with central lines placed into the bloodstream. However, most patients are now managed without central lines. A device called a NICOM (noninvasive cardiac output monitor) which monitors patients' heart function, using a few patches which are attached to their chest, may be useful in managing fluid levels without central lines. This study will compare the fluid balance in patients who are managed with typical care to the fluid balance in patients who are managed with the NICOM device.


Description:

BACKGROUND:

Negative fluid balance in acute respiratory distress syndrome (ARDS) has been shown to improve intensive care unit (ICU) length of stay and ventilator-free days. Although protocols exist for fluid management, all require invasive hemodynamic monitoring. Despite the large evidence base supporting the use of invasive monitoring, the majority of ARDS patients are now managed without invasive central lines. A non-invasive protocol for managing fluid status in patients with ARDS has not been rigorously implemented nor studied within a randomized controlled trial.

OBJECTIVE:

The study objective is to compare a novel non-invasive parameter-guided protocol for fluid management to usual care. The specific aims are: 1) to compare the incidence of new or worsening renal failure, the incidence of new or worsening shock, and the incidence of new or worsening non-shock hypotension; 2) to compare the relative effectiveness of the 2 treatment groups as assessed by cumulative fluid balance over 7 days; 3) to determine if the non-invasive protocol increases the number of ventilator-free days and ICU-free days; and further, to evaluate if it decreases 60-day mortality; and 4) to document the clinical instances where treatment digression between the 2 groups occurs.

STUDY DESIGN:

This study is a single-blinded, randomized control trial, comparing 1 treatment arm to usual care. We will treat patients with severe hypoxemic respiratory failure (including ARDS) for 7 consecutive days. Their post-study course will be monitored for a period of 60 days or until death. Patients who are randomized to the intervention group will receive fluid management strategies that are dictated by non-invasively derived (via the "NICOM" device) surrogates of cardiac preload and output. Patients who are randomized to the control group will receive standard-of-care "best practice" fluid management, as dictated by the treating physician.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria

- =18 years of age

- Acute respiratory failure (must meet ONE of the following)

- Receipt of mechanical ventilation

- Receipt of non-invasive ventilation via BIPAP or CPAP, used for an indication other than sleep apnea

- Receipt of high flow nasal cannula oxygenation with FiO2 > .4 and a flow rate > 30 LPM

- Increased total body fluid volume (any of the following)

- > 1 kg increased weight gain (compared to admission)

- > 1 L positive fluid balance (compared to admission)

- Bedside clinician determination

Exclusion Criteria

- Known pregnancy (a negative pregnancy test is required for women of child-bearing potential)

- Dialysis dependence, at the time of enrollment

- Chronic ventilator dependence, prior to admission

- Intubation for airway protection (solely for a surgical procedure) or upper airway obstruction

- Neuromuscular disease that impairs the ability to ventilate spontaneously, such as C5 or higher spinal cord injury, amyotrophic lateral sclerosis, Guillain-Barré Syndrome, and myasthenia gravis

- Solid organ transplantation or bone marrow transplantation

- Vasculitis with diffuse alveolar hemorrhage

- Severe chronic liver disease (Child-Pugh Score 10-15)

Study Design


Related Conditions & MeSH terms

  • Acute Lung Injury
  • Respiratory Distress Syndrome, Adult
  • Respiratory Distress Syndrome, Newborn

Intervention

Other:
NICOM-Guided Diuresis
NICOM-based assessment of PLR-induced change in cardiac index
Standard of Care


Locations

Country Name City State
United States Intermountain Medical Center Murray Utah

Sponsors (1)

Lead Sponsor Collaborator
Intermountain Health Care, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite incidence of new acute kidney injury (AKI), new hypotension (mean arterial blood pressure < 60 following diuresis), and new shock (SOFA (Sequential Organ Failure Assessment) score) Primary predictor is diuresis treatment protocol arm Admission to ICU through discharge from ICU
Primary 7-day cumulative fluid balance Primary predictor is diuresis treatment protocol arm Days 1 to 7
Primary Correlation of non-invasive NICOM derived cardiac parameters with incidence of new acute kidney injury (AKI), new hypotension, and new shock Primary predictor is NICOM-derived percent (%) change in stroke volume index Admission to ICU through discharge from ICU
Secondary Incidence of new kidney injury New kidney injury is defined by an increase in serum creatinine, adjusted for a fluid balance of 50%, or an absolute increase in serum creatinine of more than 0.3-mg/dL over a 48-hour window during study days 1-7 Days 1-7
Secondary Ventilator-free days to day 28 (days alive and free from mechanical ventilation) Admission to ICU to day 28 after admission to ICU
Secondary ICU-free days to day 28 (days alive and out of the ICU) Admission to ICU to day 28 after admission to ICU
Secondary 60-day mortality Admission to ICU to 60 days after admission to ICU
Secondary Incidence of new shock between the treatment arms (NICOM-guided diuresis, usual care) Admission to ICU through discharge from ICU
See also
  Status Clinical Trial Phase
Completed NCT03712215 - STUDY OF ELECTRICAL STIMULATION IN PULMONARY FUNCTION IN INTENSIVE CARE UNIT N/A
Completed NCT04582201 - Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2 Phase 1/Phase 2
Recruiting NCT01990456 - Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study N/A
Completed NCT01167621 - Changes in Refractory Acute Respiratory Distress Syndrome (ARDS) Patients Under High Frequency Oscillation-ventilation N/A
Terminated NCT00233207 - IC14 Antibodies to Treat Individuals With Acute Lung Injury Phase 2
Completed NCT00029328 - Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Phase 1/Phase 2
Completed NCT00004494 - Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis Phase 1
Completed NCT00000579 - Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) Phase 3
Recruiting NCT03236272 - Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)
Withdrawn NCT04508933 - Comparison of Extra Vascular Lung Water Index in Covid-19 ARDS and "Typical"ARDS Patients
Completed NCT02273687 - Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department N/A
Recruiting NCT03424798 - Measuring Heart and Lung Function in Critical Care N/A
Recruiting NCT01992237 - Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients N/A
Completed NCT00719446 - Evaluating Health Outcomes and QOL After ALI Among Participants of the ALTA, OMEGA, EDEN, and SAILS ARDS Network Trials N/A
Completed NCT00236262 - Effect of Positive Expiratory Pressure on Right Ventricular Function in Patients With Respiratory Distress Syndrome N/A
Completed NCT00157144 - Australia and New Zealand Adult Extracorporeal Membrane Oxygenation (ECMO) Audit 2005 N/A
Completed NCT00300248 - Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome N/A
Completed NCT00141726 - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Phase 2
Recruiting NCT00465374 - A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients Phase 3
Completed NCT00094406 - Carbon Monoxide to Prevent Lung Inflammation Phase 1